OakChart

Equillium Inc

EQHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

1.42-0.04 (-2.41%)
2026-11-12 00:07 CET
Market cap
92.26 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-18.01 USD m
Free cash flow, TTM
-20.09 USD m
EPS diluted, TTM
-0.20
P/E
-
Compare

Price

EQ against its 20, 50 and 200-day averages
2050200beatmiss
2.003.002.6M5.2MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26EQclose 1.4220-day 1.3650-day 1.63200-day 2.091.4252w high

59.9% under the 52-week high of 3.54 on 30 Jun 2026. 52-week low 0.76 on 14 Nov 2025. Last 15 sessions, 37.6% high to low

Volume 0.39× normal · the line is the 50-bar volume average

Profile

EQ
52-week range, 24% of the way up
0.763.54

Equillium, Inc. is a clinical-stage biotechnology company that engages in the development of novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly in March 2017 and is headquartered in La Jolla, CA.

Employees14
IPOOct 12, 2018
Beta2.03
ATR, 14d0.13
Rel volume0.39
Short float11.70%
Insider own20.17%
Inst own60.59%

Snapshot

6 groups

Valuation

Index-
Market Cap90.04M
Enterprise Value33.46M
Income-18.01M
Sales0.00M
Book/sh0.88
Cash/sh0.90
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees14
IPOOct 12, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.61
P/C1.58
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio23.40
Current Ratio23.40
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.20
EPS next Y-0.23
EPS next Q-0.05
EPS this Y47.44%
EPS next Y-10.24%
EPS next 5Y11.09%
EPS past 3/5Y40.45% 23.22%
Sales past 3/5Y- -
EPS Y/Y TTM64.23%
Sales Y/Y TTM-100.00%
EPS Q/Q73.86%
Sales Q/Q-
EarningsAug 13 AMC
EPS/Sales Surpr.25.93% -

Ownership

Insider Own20.17%
Insider Trans-3.08%
Inst Own60.59%
Inst Trans-3.00%
ROA-50.68%
ROE-58.98%
ROIC-32.05%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA204.12%
SMA50-12.71%
SMA200-32.00%
Trades-

Technical

Shs Outstand63.41M
Shs Float50.62M
Short Float11.70%
Short Ratio10.82
Short Interest5.92M
52W High3.54 -59.89%
52W Low0.76 87.78%
Volatility11.04% 10.24%
ATR (14)0.13
RSI (14)47.63
Beta2.03
Rel Volume0.39
Avg Volume547.69K
Volume215,144

Performance

Perf Week1.43%
Perf Month7.58%
Perf Quarter-29.35%
Perf Half Y-38.53%
Perf YTD-8.39%
Perf Year46.24%
Perf 3Y186.52%
Perf 5Y-74.96%
Perf 10Y-
Recom1.00
Target Price8.60
Prev Close1.46
Price1.42
Change %-2.41%

Analyst ratings

latest 10 of 15
DateActionAnalystRating changeTargetImplied
Oct 12, 2026ResumedLLeerink PartnersOutperform$6+322.5%
Jul 13, 2026InitiatedPPiper SandlerOverweight
May 28, 2026UpgradeLLeerink PartnersMarket Perform → Outperform$6+322.5%
Apr 23, 2026InitiatedOOppenheimerOutperform$7+393.0%
Apr 16, 2026InitiatedRB. Riley SecuritiesBuy$6+322.5%
Apr 14, 2026InitiatedRRaymond JamesStrong Buy$6+322.5%
Apr 07, 2026InitiatedCCantor FitzgeraldOverweight$10+604.2%
Mar 13, 2026InitiatedRRoth CapitalBuy$12+745.1%
Feb 25, 2026InitiatedSStifelBuy$5+252.1%
Mar 28, 2025DowngradeLLeerink PartnersOutperform → Market Perform$3 → $1-29.6%

Peers

Mkt cap
TickerCompanyMkt cap
PALIPalisade Bio Inc203.90M
IMUXImmunic Inc110.79M
ABVXAbivax ADR8.01B
PTGXProtagonist Therapeutics Inc8.80B
SYRESpyre Therapeutics Inc10.14B
CNTBConnect Biopharma Holdings Ltd43.38M
ALMSAlumis Inc883.74M
KYMRKymera Therapeutics Inc11.51B
RLYBRallybio Corp85.07M
ENTXEntera Bio Ltd560.73M

Insider trading

latest 14 of 32
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Connelly StephenOfficerJun 05 '26Proposed Sale2.9430,97591,070Jun 05 05:07 PM
Zedelmayer ChristineSr. Vice President and COOJun 05 '26Option Exercise0.7914,58411,44877,170Jun 05 04:42 PM
Zedelmayer ChristineSr. Vice President and COOJun 05 '26Sale2.9314,58442,73762,586Jun 05 04:42 PM
Connelly StephenPresident and CSOJun 04 '26Sale3.16200,000632,760793,000Jun 05 04:42 PM
Connelly StephenPresident and CSOJun 05 '26Sale2.9430,97591,070762,025Jun 05 04:42 PM
Connelly StephenOfficerJun 04 '26Proposed Sale3.16200,000632,760Jun 04 05:30 PM
Tom PennyPrincipal Accounting OfficerMay 28 '26Option Exercise0.7965,00051,02565,000May 29 06:28 PM
Tom PennyPrincipal Accounting OfficerMay 28 '26Sale2.9565,000191,7500May 29 06:28 PM
Zedelmayer ChristineSr. Vice President and COOMay 28 '26Option Exercise0.7786,01266,391118,390May 29 06:19 PM
Zedelmayer ChristineSr. Vice President and COOMay 27 '26Option Exercise0.779,8217,56272,407May 29 06:19 PM
Zedelmayer ChristineSr. Vice President and COOMay 28 '26Sale2.8086,012240,69362,586May 29 06:19 PM
Zedelmayer ChristineSr. Vice President and COOMay 27 '26Sale2.709,82126,51762,586May 29 06:19 PM
Zedelmayer ChristineOfficerMay 27 '26Proposed Sale2.6365,625172,593May 27 04:14 PM
Zedelmayer ChristineSr. Vice President and COOMar 13 '26Option Exercise0.79120,31294,445182,898Mar 16 06:53 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B
QQQSInvesco NASDAQ Future Gen 200 ETFAUM: 20.53M

News

latest 14 of 200
  • Equillium to Participate in Upcoming Investor Conferences (GlobeNewswire) +13.53%
  • Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504 (GlobeNewswire)
  • Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference (GlobeNewswire)
  • Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504 (GlobeNewswire)
  • Equillium Announces Poster Presentations at the 7th International AHR Conference (GlobeNewswire)
  • Equillium to Participate in Stifel's 2026 Virtual Immunology and Inflammation Forum (GlobeNewswire) -9.51%
  • Equillium to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire) -7.80% +17.41%
  • Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.42% +11.47%
  • Equillium to Participate in the 2026 Jefferies Global Healthcare Conference (GlobeNewswire) +7.98%
  • Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis (GlobeNewswire) +16.71% +7.28%
  • Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire) +12.12%
  • Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Equillium to Participate in Oppenheimer's 2026 Innovation on the Island Event (GlobeNewswire) +6.97%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-0.040-0.054-0.0400.000.0010
2026Q12026-05-13-0.060-0.046-0.0550.000.007
2025Q42026-03-25-0.040-0.060-0.0410.000.004
2025Q32025-11-13-0.060-0.070-0.0650.000.001
2025Q22025-08-06-0.160-0.230-0.1610.000.001
2025Q12025-05-08-0.410-0.335-0.2430.000.002
2024Q42025-03-27-0.160-0.310-0.1634.390.002
2024Q32024-11-130.0000.0180.00012.1611.554
2024Q22024-08-080.010-0.1500.01313.856.334
2024Q12024-05-09-0.080-0.148-0.07810.696.834
2023Q42024-03-25-0.070-0.168-0.0679.216.434
2023Q32023-11-08-0.110-0.180-0.1068.876.434
2023Q22023-08-09-0.100-0.168-0.0979.126.456
2023Q12023-05-11-0.110-0.210-0.1158.885.616
2022Q42023-03-230.0800.1960.08115.7618.005
2022Q32022-11-14-0.400-0.370-0.3980.000.005

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.470-1.423-1.4730.000.00
2020FY-1.460-1.538-1.4650.000.00
2021FY-1.360-1.335-1.3560.000.00
2022FY-1.850-1.670-1.85115.7618.00
2023FY-0.380-0.500-0.38436.0833.37
2024FY-0.230-0.375-0.22841.1036.85
2025FY-0.390-0.413-0.3970.000.00
2026FY--0.205--0.00
2027FY--0.226--0.00
2028FY--0.274--0.00
2029FY--0.327--0.00
2030FY--0.402--0.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-146000.000.000.00
2026Q3S2026-08-136000.000.000.00
2026Q3S2026-07-106000.000.000.00
2026Q3S2026-05-275000.000.000.00
2026Q3S2026-05-144000.000.000.00
2026Q3S2026-04-143000.000.000.00
2026Q3S2026-04-062000.000.000.00
2026Q3S2026-03-261000.000.000.00
2026Q3S2026-03-122000.000.000.00
2026Q3S2025-11-141000.000.000.00
2026Q3R2026-10-28500-0.05-0.06-0.04
2026Q3R2026-10-09501-0.05-0.06-0.04
2026Q3R2026-08-14401-0.05-0.06-0.04
2026Q3R2026-08-13401-0.05-0.06-0.04

Estimate history

EPS, annual-0.13-1.087-1.473-1.465-1.356-1.851-0.384-0.228-0.391-0.203
Period201720182019202020212022202320242025TTM
EPS, quarterly0.0130-0.163-0.243-0.161-0.065-0.041-0.055-0.042
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000015.75936.08441.09500
Period201720182019202020212022202320242025TTM
Sales, quarterly13.85312.1614.392000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual17.45417.37617.42624.75329.45634.41435.25535.55861.46463.408
Period201720182019202020212022202320242025MRQ
Shares, quarterly35.42435.42435.55835.71935.71960.67761.46463.22763.408
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.0041.0936.0815.760.000.000.000.00
Cost of Goods Sold Incl. D&A0.100.120.140.130.120.070.040.020.01
Gross Profit-0.10-0.1240.9635.9615.64-0.07-0.04-0.02-0.01
Selling, General and Administrative Excl. Other19.2023.5249.2350.4854.6737.7129.5026.708.61
Research and Development8.5812.8437.4337.0437.5526.3819.3817.644.94
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-19.30-23.63-8.27-14.52-39.03-37.79-29.55-26.73-8.62
Interest Expense0.000.000.000.491.051.071.100.282.56
Unusual Expense0.000.000.000.0023.050.000.000.002.42
Net Income Before Taxes-18.01-22.40-7.71-12.76-62.43-39.05-29.81-25.60-13.25
Income Taxes0.000.000.360.580.000.000.000.000.00
Consolidated Net Income-18.01-22.40-8.07-13.34-62.43-39.05-29.81-25.60-13.25
Net Income From Continuing Operations-18.01-22.40-8.07-13.34-62.43-39.05-29.81-25.60-13.25
Net Income-18.01-22.40-8.07-13.34-62.43-39.05-29.81-25.60-13.25
EPS (Recurring)-0.16-0.39-0.23-0.38-1.37-1.36-1.46-1.47-0.95
EPS (Basic, Before Extraordinaries)-0.20-0.39-0.23-0.38-1.85-1.36-1.46-1.47-1.09
EPS (Diluted)-0.20-0.39-0.23-0.38-1.85-1.36-1.46-1.47-1.09
EBITDA-19.20-23.52-8.13-14.40-38.91-37.71-29.50-26.70-8.61
Non-Operating Income (Expense)1.291.240.562.260.70-0.190.831.410.34
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.162.322.963.164.844.413.822.250.44
Price To Sales Ratio--0.640.702.27----
Gross Margin--99.6799.6599.25----
Operating Margin---20.12-40.24-247.65----
Net Margin---19.63-36.96-396.14----
Shares Outstanding63.4161.4635.5635.2534.4129.4624.7517.4317.38
Market Capitalization92.2692.2626.5125.3936.41110.80132.2958.73141.79

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.004.3912.16
Cost of Goods Sold Incl. D&A0.030.020.020.030.030.030.040.04
Gross Profit-0.03-0.02-0.02-0.03-0.03-0.034.3612.13
Selling, General and Administrative Excl. Other5.135.593.944.556.208.849.0512.80
Research and Development2.752.991.541.304.085.927.329.56
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-5.16-5.61-3.96-4.58-6.23-8.87-4.70-0.68
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-4.69-5.31-3.77-4.23-5.74-8.65-5.43-0.01
Income Taxes0.000.000.000.000.000.000.360.00
Consolidated Net Income-4.69-5.31-3.77-4.23-5.74-8.65-5.79-0.01
Net Income From Continuing Operations-4.69-5.31-3.77-4.23-5.74-8.65-5.79-0.01
Net Income-4.69-5.31-3.77-4.23-5.74-8.65-5.79-0.01
EPS (Recurring)-0.04-0.06-0.04-0.06-0.16-0.24-0.16-0.00
EPS (Basic, Before Extraordinaries)-0.04-0.06-0.04-0.06-0.16-0.24-0.16-0.00
EPS (Diluted)-0.04-0.06-0.04-0.06-0.16-0.24-0.16-0.00
EBITDA-5.13-5.59-3.94-4.55-6.20-8.84-4.66-0.64
Non-Operating Income (Expense)0.460.300.190.340.490.22-0.730.67
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.090.930.740.400.440.620.031.00
Price To Sales Ratio---21.270.680.460.650.64
Gross Margin------99.2099.71
Operating Margin-------106.97-5.58
Net Margin-------131.92-0.06
Shares Outstanding63.4163.2361.4660.6835.7235.7235.5635.42
Market Capitalization92.26126.4594.3885.0911.2613.9026.5129.47

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments30.2822.5740.8771.0280.7182.1653.1465.917.10
Short Term Receivables0.111.146.292.840.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.651.262.202.872.663.012.291.190.05
Total Current Assets31.0424.9849.3576.7383.3785.1755.4367.107.15
Net Property, Plant & Equipment0.820.631.111.581.880.240.090.060.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets-0.00-----0.000.00
Deferred Tax Assets0.160.12-------
Other Assets0.030.000.070.100.150.010.010.000.00
Total Assets32.0525.7350.5378.4285.4185.4355.5467.167.15
Short Term Debt Incl. Current Port. of LT Debt0.360.200.446.121.801.670.000.000.00
Accounts Payable0.762.684.713.981.232.771.871.120.00
Income Tax Payable0.000.36-------
Other Current Liabilities1.823.1222.4321.945.892.812.010.910.57
Total Current Liabilities2.936.3627.5732.048.917.253.882.030.57
Long Term Debt0.360.190.384.069.988.289.680.008.06
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.160.12-------
Other Liabilities0.000.000.0010.380.000.050.130.200.78
Total Liabilities3.456.6727.9646.4818.9015.5713.692.239.40
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity28.6019.0622.5731.9466.5069.8541.8564.94-2.25
Total Shareholders Equity28.6019.0622.5731.9466.5069.8541.8564.94-2.25
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity28.6019.0622.5731.9466.5069.8541.8564.94-2.25
Total Liabilities & Stockholders Equity32.0525.7350.5378.4285.4185.4355.5467.167.15
Book Value Per Share0.470.540.640.932.262.822.403.74-0.13
Tangible Book Value Per Share0.470.540.640.932.262.822.403.74-0.13
Full-Time Employees1435443645311611-
Price to Book Ratio1.651.141.051.291.671.901.412.18-8.38
Return on Assets-77.53-21.16-20.68-76.21-45.72-42.30-41.73-35.66-
Return on Equity-93.99-38.75-48.92-126.83-57.28-53.38-47.95-42.28-
Return on Invested Capital-77.36-41.91-58.09-173.39-51.06-38.16-49.68-20.41-38.95
Quick Ratio10.583.931.792.409.3511.7614.2833.0912.57
Current Ratio10.583.931.792.409.3511.7614.2833.0912.57

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-18.01-22.40-8.07-13.34-62.43-39.05-29.81-25.60-13.25
Depreciation0.100.120.140.130.120.070.040.020.01
Other Funds (Non Cash)3.171.85-11.94-6.0353.565.203.891.925.42
Funds from Operations-14.73-20.43-19.87-19.24-8.75-33.78-25.88-23.66-7.83
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-5.24-2.320.84-2.550.021.701.250.710.30
Cash from Operating Activities-19.97-22.75-19.03-21.78-8.73-32.08-24.62-22.95-7.53
Capital Expenditures-0.12-0.05-0.09-0.05-0.28-0.06-0.20-0.07-0.03
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.010.010.000.000.700.000.000.00-
Purchase or Sale of Investments0.004.5013.90-4.7118.2627.46-18.39-2.09-37.40
Purchase of Investments0.000.00-17.60-54.71-14.96-32.99-55.51-54.62-37.40
Sale Or Maturity of Investments0.004.5031.5050.0033.2360.4537.1252.530.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.114.4613.81-4.7618.6827.41-18.59-2.17-37.43
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock65.7430.430.16-0.100.2131.0653.95-0.0464.77
Repurchase of Common Pref Stock0.000.000.00-0.260.000.000.000.000.00
Sale of Common Pref Stock65.7430.430.160.170.2131.0653.95-0.0464.77
Proceedsfrom Stock Options63.3628.590.160.170.2130.1753.94-0.1164.48
Issuance or Reduction of Debt, Net0.000.000.00-9.13-1.430.000.009.881.60
Change in Long Term Debt0.000.000.00-9.13-1.430.000.009.881.60
Issuance of Long Term Debt0.000.000.000.000.000.000.009.881.60
Reduction of Long Term Debt0.000.000.00-9.13-1.430.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities65.7430.430.16-9.23-1.2231.0653.959.8466.37
Exchange Rate Effect0.010.05-0.08-0.120.01-0.000.03-0.01-
Net Change in Cash45.6712.19-5.13-35.898.7426.3810.76-15.2921.40
Free Cash Flow-20.09-22.79-19.11-21.83-9.01-32.14-24.83-23.02-7.56
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments57.1661.3230.2833.1211.4914.50
Short Term Receivables0.000.000.110.120.041.04
Inventories0.000.000.000.000.000.00
Other Current Assets0.810.950.650.340.420.67
Total Current Assets57.9862.2731.0433.5811.9516.22
Net Property, Plant & Equipment0.660.780.820.930.450.51
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets---0.000.000.00
Deferred Tax Assets--0.16---
Other Assets0.030.030.030.000.000.00
Total Assets58.6763.0832.0534.5112.4016.73
Short Term Debt Incl. Current Port. of LT Debt0.410.440.360.270.150.15
Accounts Payable0.851.290.761.084.813.06
Income Tax Payable--0.000.020.020.36
Other Current Liabilities1.221.611.821.722.252.43
Total Current Liabilities2.483.352.933.097.236.00
Long Term Debt0.170.250.360.470.110.15
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--0.16---
Other Liabilities0.000.000.000.000.000.00
Total Liabilities2.653.603.453.577.346.15
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity56.0259.4928.6030.945.0610.58
Total Shareholders Equity56.0259.4928.6030.945.0610.58
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity56.0259.4928.6030.945.0610.58
Total Liabilities & Stockholders Equity58.6763.0832.0534.5112.4016.73
Book Value Per Share0.880.940.470.510.140.30
Tangible Book Value Per Share0.880.940.470.510.140.30
Full-Time Employees--14---
Price to Book Ratio1.654.303.0410.101.060.73
Return on Assets-50.68-47.75-77.53-70.81-73.09-46.37
Return on Equity-58.98-54.39-93.99-90.24-146.92-88.32
Return on Invested Capital-8.35-8.89-13.04-13.47-111.11-80.67
Quick Ratio23.4018.6210.5810.851.652.70
Current Ratio23.4018.6210.5810.851.652.70

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-4.69-5.31-3.77-4.23-5.74-8.65
Depreciation0.030.020.020.030.030.03
Other Funds (Non Cash)1.130.940.810.290.190.56
Funds from Operations-3.53-4.35-2.94-3.91-5.51-8.06
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.570.05-0.19-4.522.50-0.11
Cash from Operating Activities-4.11-4.30-3.13-8.43-3.01-8.17
Capital Expenditures-0.07-0.00-0.040.000.00-0.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.010.000.000.00
Purchase or Sale of Investments0.000.000.000.000.004.50
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.004.50
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.07-0.00-0.030.000.004.50
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.0435.350.2830.07-0.020.09
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.0435.350.2830.07-0.020.09
Proceedsfrom Stock Options-0.0934.90-0.3228.88-0.020.05
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.0435.350.2830.07-0.020.09
Exchange Rate Effect-0.020.000.04-0.010.02-0.00
Net Change in Cash-4.1631.05-2.8421.62-3.01-3.58
Free Cash Flow-4.18-4.30-3.18-8.43-3.01-8.17

Revenue breakdown

Pharmaceutical Preparations2024: 41.10M
United States2024: 41.10M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3011.70%5.9M50.6M577.33K
2026-10-1511.17%5.7M50.6M545.19K
2026-09-3010.95%5.5M50.6M658.13K
2026-09-1510.87%5.5M50.6M628.83K
2026-08-3110.64%5.4M50.5M833.33K
2026-08-1410.97%5.5M50.5M870.32K
2026-07-3110.77%5.4M50.3M814.36K
2026-07-1511.07%5.6M50.3M801.38K
2026-06-3010.17%5.1M50.3M659.85K
2026-06-159.36%4.7M50.3M613.02K
2026-05-297.48%3.6M48.3M469.10K
2026-05-155.95%2.9M48.3M430.66K
2026-04-305.83%2.8M48.3M484.00K
2026-04-156.01%2.8M45.9M506.61K
2026-03-316.04%2.7M45.1M542.17K
2026-03-134.59%2.0M43.5M694.79K
2026-02-274.79%2.1M43.5M648.64K
2026-02-134.52%2.0M43.5M673.25K
2026-01-303.07%1.3M43.6M657.28K
2026-01-153.38%1.5M43.6M666.48K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.100.003.6640.000.000.258-0.0150.001
call5.000.000.500.005.6580.000.000.194-0.0190.001
call7.500.000.250.006.7360.000.000.176-0.0210.001
put2.500.501.601.208.8085.000.00-0.743-0.0150.001
put5.002.505.100.000.0000.000.00-0.804-0.0210.001
put7.505.007.600.000.0000.000.00-0.821-0.0230.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-04SCHEDULE 13G/ASEC
2026-10-268-KCurrent report2026-10-26SEC
2026-10-058-KCurrent report2026-10-05SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-13SCHEDULE 13GSEC
2026-08-12SCHEDULE 13G/ASEC
2026-06-05144Filing for proposed sale of securities under Rule 144.SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-04144Filing for proposed sale of securities under Rule 144.SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-294Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-05-298-KCurrent report2026-05-28SEC
2026-05-27144Filing for proposed sale of securities under Rule 144.SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-138-KCurrent report2026-05-13SEC
2026-05-07SCHEDULE 13GSEC
2026-04-16EFFECTEffectiveness filing by commission orderSEC
2026-04-15ARSAnnual report to security holders. 2025-12-31SEC
2026-04-15DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-15DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-28SEC
2026-04-14CORRESPSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-0600766.57K3
2026-0500458.96K3
2026-040000
2026-0300663.25K2
2026-0200328.10K1
2026-01008.43K1
2025-1200197.49K3
2025-11007.70K1

Institutional holders

Manager% owned
Jupiter Topco LLC10.27%
Decheng Capital LLC7.03%
Aberdeen Group plc7.03%
Affinity Asset Advisors, LLC6.48%
ADAR1 Capital Management, LLC5.94%
Woodline Partners LP5.54%
RA CAPITAL MANAGEMENT, L.P.4.90%
STEMPOINT CAPITAL LP3.19%
VANGUARD CAPITAL MANAGEMENT LLC2.88%
Eversept Partners, LP2.41%

Funds

Fund% owned
abrdn Life Sciences Investors5.74%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.22%
VANGUARD EXTENDED MARKET INDEX FUND0.54%
Fidelity Extended Market Index Fund0.26%
iShares Micro-Cap ETF0.23%
Avantis U.S. Small Cap Equity ETF0.12%
Fidelity Total Market Index Fund0.09%
Fidelity Series Total Market Index Fund0.08%
Invesco NASDAQ Future Gen 200 ETF0.06%
TIFF MULTI-ASSET FUND0.05%

OakChart. EQ. Cached 15 minutes.